All In Biotech

Drug Trial Radar · NCT02101957

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

96

Actual

Start

Oct 2010

Primary completion

Jul 2015

Sponsor

Lead sponsor
University Hospital, AngersGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effect of cysteamine in patients with symptomatic Huntington's disease by comparing two groups of patients (cysteamine vs placebo) on the results of the Unified Huntington's Disease Rating Scale (UHDRS, Huntington study group 1996).

Conditions

  • Huntington's Disease

Interventions

  • RP103Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Unified Huntington's Disease Rating Scale motorTime frame: at 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Angers

    Angers, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.